Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

QurAlis targets UNC13A RNA mis-splicing in ALS and FTD with novel FlexASO platform

The latest program by QurAlis aims to correct mis-splicing in the UNC13A gene, a critical factor in ALS and FTD.

By Brian Buntz | March 20, 2023

QurAlisQurAlis, a privately-held company specializing in precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has debuted its latest program. This initiative targets UNC13A RNA mis-splicing, a critical gene alteration present in ALS and frontotemporal dementia (FTD). FTD has recently gained renewed attention following the disclosure of Bruce Willis’ diagnosis of the condition. UNC13A is a vital regulator of neurotransmitter release at synapses, and the genetic alteration resulting in mis-splicing is estimated to occur in 58% of ALS patients and up to half of FTD cases.

To tackle this gene alteration, QurAlis has developed its proprietary FlexASO splice modulator platform. This technology uses antisense oligonucleotides (ASOs) to correct mis-splicing, restore UNC13A protein production, and reduce cryptic exons that may contribute to disease progression. Kasper Roet, QurAlis CEO, explained that “FlexASOs operate on the same mechanism of action as other splice-switching ASOs. However, incorporation of FlexASO technology improves the potency, safety, and biodistribution of oligos.”

QurAlis identified the critical genetic alteration in UNC13A as a key target for developing precision medicines for sporadic ALS and FTD populations through careful analysis of the gene’s pre-mRNA. Roet noted that UNC13A was previously identified as an ALS and FTD disease gene, supporting its importance in the development of disease. The company’s research team has focused on restoring the UNC13A protein and cellular function in ALS and FTD disease models.

“The development of appropriate human disease models was very complex,” Roet said. “We have resolved this by a dedicated group of researchers within our leading stem cell modeling group under the leadership of Sandy Hinckley our head of discovery.” 

FlexASO’s future impact on patients’ lives

Roet expressed enthusiasm for the UNC13A program, which is the company’s third initiative focused on a genetic target for developing precision medicines for sporadic ALS and FTD populations. “We look forward to advancing our UNC13A program along with our two lead clinical programs in ALS and a robust pipeline so that we can make a real difference in patients’ lives,” he said. Roet anticipates that the UNC13A therapy could significantly improve the lives of ALS and FTD patients by potentially slowing or halting disease progression.

Dr. Angela Genge, chief medical officer of QurAlis, will introduce the company’s UNC13A program during an oral presentation at the 2023 Muscular Dystrophy Association (MDA) Clinical and Scientific Congress. Dr. Genge’s presentation, “Gene Directed Therapy for Sporadic ALS,” is scheduled for March 21, 2023.

QurAlis believes the FlexASO splice modulator platform offers the potential to significantly impact the treatment of ALS and FTD.

As QurAlis unveils its latest program to address ALS and FTD, the journey to better understand and develop treatments for these complex neurodegenerative diseases continues. While challenges remain, the scientific community’s collective efforts in unraveling the mysteries of these conditions offer hope for patients and their families as they navigate the road towards potential therapies. Having recently closed an oversubscribed $88 million Series B financing, the company should be well-funded for the endeavor.


Filed Under: Neurological Disease
Tagged With: ALS, antisense oligonucleotides, FlexASO splice modulator platform, frontotemporal dementia, gene's pre-mRNA, human stem cell modeling, neurodegenerative diseases, QurAlis, sporadic ALS, UNC13A protein, UNC13A RNA mis-splicing
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE